Financial News

Financial Report: West

Contract-Manufactured Products segment sales up 18% in the quarter

West
4Q Revenues: $415.6 million (+9%)
4Q Earnings: n/a (earnings were $39.1 million 4Q16)
FY Revenues: $1.6 billion(+6%)
FY Earnings: $150.7 million (+9%)
Comments: Proprietary Products segment sales were up 6% to $306.4 million in the quarter led by double-digit growth in Biologics and high-single digit growth in Generics, offset by a low-single digit decline in Pharma. Contract-Manufactured Products segment sales were up 18% to $109.2 million. During the three and twelve months ended December 31, 2017, the company recorded a tax charge of $48.8 million due to the estimated impact of U.S. tax reform, including the repatriation tax on accumulated foreign earnings.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters